Dr. Farhad Khimani, MD

Dr. Khimani practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Khimani's NPI, 1376792911, was assigned on September 18, 2008. Dr. Khimani graduated from Aga Khan Medical College in 2005. Dr. Khimani holds Florida license ME124476.

Dr. Khimani's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Khimani's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Khimani to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khimani practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Khimani's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Khimani is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Khimani's licenses on file in 2 states: Florida and West Virginia.

Dmand AI lists breast cancer, chronic leukemia, immune deficiency disease, lymphoma and multiple myeloma among the conditions Dr. Khimani treats.

CMS data shows 308 Medicare services from Dr. Khimani across 3 procedure codes in 2024, for 77 Medicare patients. Medicare paid $25,408 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 77 Medicare patients who saw Dr. Khimani in 2024. The largest group is 65 to 74, with 47 patients. 73% of them have high blood pressure, and 61% have high cholesterol. 14% are also on Medicaid. Their average risk score is 3.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khimani's median patient age at 62, with 43% women.

In 2024, Dr. Khimani wrote 784 Medicare Part D claims for 81 patients. 86% of them were for generic drugs. CMS names the drug for 558 of them, across 19 drugs with 11 or more claims each, at $1,287,030 in total drug cost. In 2023, CMS named 394 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Khimani for performance year 2024, reported as part of a group. Dr. Khimani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Khimani as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 61 papers to Dr. Khimani, published from 2013 to 2025. 2024 was the busiest year, with 9. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Immunotherapy, Adoptive. Dr. Khimani has published most often in Transplant Cell Ther. Dr. Khimani's most frequent co-authors are Taiga Nishihori, MD, Frederick Lundry Locke, MD and Asmita Mishra, MD.

Dmand AI links Dr. Khimani to 5 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Exanthema, Graft vs Host Disease and Leukemia, Biphenotypic, Acute. Center for International Blood and Marrow Transplant Research sponsors the most, 2.

CMS Open Payments shows 11 general payments to Dr. Khimani from 5 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 86% of the total. Sanofi and Genzyme US Companies paid the most, $553.

Dr. Khimani graduated from Aga Khan Medical College in 2005.

Dr. Khimani is in network with 11 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.